Ergocristine is an ergopeptine and one of the ergot alkaloids. It is a peptide-containing ergoline derivative in which lysergic acid is amide-bonded to a cyclic tripeptide; this confers high lipophilicity and a complex stereochemical profile that affects receptor binding and chromatographic behavior. The molecule is produced naturally by Claviceps species and is characterized by a rigid ergoline core fused to a peptide moiety, giving it affinity for adrenergic and certain serotonergic receptors and producing pronounced vasoconstrictive pharmacology in bioassays. As of February 24, 2010 ergocristine has been federally regulated. Because of the existing Controlled Substances Act regulatory controls on the LSD precursors lysergic acid, lysergic acid amide, laboratories and suppliers need to account for precursor controls and record keeping; procurement, possession and transfer of ergocristine are often subject to licensing, reporting and secure storage requirements. For product pages and technical specifications list the CAS registry number, typical form and storage conditions, and recommended analytical identity tests such as HPLC with UV detection and confirmatory LC-MS without providing synthetic or procedural details.
Parent: Ergocristine
Typical quality specifications for research or reference-grade ergocristine emphasize high purity and tight control of related ergot alkaloids and degradants. A representative specification can include assay by validated HPLC equal to or greater than 98.0 percent w w, individual related ergot alkaloid impurities such as ergocristinine, ergocryptine, ergocornine or ergotamine limited to not more than 0.5 percent each w w, total related impurities not exceeding 2.0 percent w w, and unspecified impurities combined below 0.5 percent w w. Residual solvents and volatile impurities should meet applicable ICH Q3C limits and elemental impurities should be controlled to accepted pharmacopeial thresholds, for example single metal elements below 10 ppm where relevant. Identity confirmation is routinely performed by orthogonal methods such as LC-MS and UV spectral matching and stereoisomer content is monitored because epimerization to inactive isomers can occur under improper storage.
Ergocristine is an ergot-derived ergopeptine consisting of lysergic acid linked to a cyclic tripeptide; it is an ergot alkaloid with vasoconstrictive activity and a complex stereochemical profile, used primarily as a research reference compound and regulated as noted above.
Ergocristine is regulated because it is an ergot alkaloid related to controlled lysergic acid derivatives and because regulatory frameworks that control LSD precursors and related substances extend record keeping, licensing and distribution controls to certain ergot alkaloids and their precursors; suppliers and users must follow applicable Controlled Substances Act and precursor control requirements.
Monitored impurities include epimers such as ergocristinine, other related ergopeptines like ergocryptine and ergocornine, and common degradants; specifications typically limit individual related impurities to 0.5 percent w w or less, total related impurities to about 2.0 percent w w, and require confirmation by orthogonal analytical methods such as HPLC and LC-MS.
